HIF-3α Inhibitors

HIF-3α inhibitors consist of a broad range of compounds that interfere with the HIF signaling pathway at different levels, including DNA binding, protein stability, and transcriptional activity. These inhibitors do not target HIF-3α directly but modulate the hypoxia signaling pathway, resulting in reduced HIF-3α activity. For example, echinomycin acts by directly blocking the DNA-binding site of HIF, thus preventing transcriptional activation of hypoxia-responsive genes. Similarly, YC-1 and digoxin disrupt the synthesis and stability of HIF-α subunits, which can lead to a decrease in HIF-3α levels or activity due to the disruption of homeostatic feedback loops within the HIF family.

Some inhibitors, like topotecan and chetomin, target the molecular machinery that HIFs depend on for their transcriptional activity, while others, such as KC7F2 and PX-478, modulate the transcriptional activity of HIFs. SAHA, celastrol, and berberine engage in indirect inhibition through epigenetic modulation or by affecting proteasomal degradation pathways, which impact HIF-3α among a multitude of cellular targets.